Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | TLR4 | O00206 | 1/20 | 0.42 |
| ▸ | SRD5A1 | P18405 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | HTR3A | P46098 | 1/20 | 0.39 |
| ▸ | LIG1 | P18858 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | CA4 | P22748 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15874655 | 1.00 | KDM4E (0.42) | KDM4ESMN1; SMN2MAPTHPGDTLR4 | |
| SCHEMBL11840693 | 0.98 | KMT2A (0.42) | KDM4ESMN1; SMN2MAPTHPGDTLR4 | |
| SCHEMBL512106 | 0.94 | SRD5A1 (0.41) | KDM4ESMN1; SMN2MAPTHPGDSRD5A1 | |
| SCHEMBL11837854 | 0.93 | CA1 (0.41) | KDM4ESMN1; SMN2MAPTHPGDTLR4 | |
| SCHEMBL15282087 | 0.86 | SRD5A1 (0.43) | KDM4ESMN1; SMN2SRD5A1HTR3ALIG1 | |
| SCHEMBL6434415 | 0.81 | ESR2 (0.48) | TLR4CA1CA2CA4 | |
| SCHEMBL19993834 | 0.81 | LMNA (0.42) | MAPTTLR4KMT2AMEN1NPSR1 | |
| SCHEMBL513149 | 0.81 | LMNA (0.42) | TLR4KMT2AMEN1LIG1CA1 | |
| SCHEMBL8381617 | 0.81 | DDB1 (0.50) | TLR4KMT2ACA1CA2CA4 | |
| SCHEMBL28649636 | 0.81 | TLR4 (0.42) | MAPTTLR4KMT2ACA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240254095-A1 | NMDA Receptor Antagonist and Use Thereof | SYNPHATEC (SHANGHAI) BIOPHARMACEUTICAL TECHNOLOGY CO., LTD. (CN) | 2024-08-01 | — | — | US | disclosed |
| EP-4339189-A1 | NMDA RECEPTOR ANTAGONIST AND USE THEREOF | Synphatec (Shanghai) Biopharmaceutical Technology Co., Ltd. (CN) | 2024-03-20 | — | — | EP | disclosed |
| CN-113234036-B | NMDA receptor antagonists and uses thereof | 斯莱普泰(上海)生物医药科技有限公司 | 2023-07-14 | — | — | CN | disclosed |
| WO-2022237849-A1 | NMDA RECEPTOR ANTAGONIST AND USE THEREOF | 中国科学院上海有机化学研究所 | 2022-11-17 | — | — | WO | disclosed |
| CN-113234036-A | NMDA receptor antagonists and uses thereof | 中国科学院上海有机化学研究所 | 2021-08-10 | — | — | CN | disclosed |
| CN-106496005-A | Synthesis method of 4- (4-chlorphenyl) cyclohexanone | 上海毕得医药科技有限公司 | 2017-03-15 | — | — | CN | disclosed |
| CN-106496005-A | Synthesis method of 4- (4-chlorphenyl) cyclohexanone | 上海毕得医药科技有限公司 | 2017-03-15 | — | — | CN | disclosed |
| CN-106496008-A | Method for synthesizing 4- (4-chlorphenyl) cyclohexanone | 上海毕得医药科技有限公司 | 2017-03-15 | — | — | CN | disclosed |
| CN-106496008-A | Method for synthesizing 4- (4-chlorphenyl) cyclohexanone | 上海毕得医药科技有限公司 | 2017-03-15 | — | — | CN | disclosed |
| WO-2014109712-A1 | PALLADIUM-CATALYZED ASYMMETRIC (HETERO)ARYLATION AND VINYLATION OF KETONE ENOLATES TO PRODUCE TERTIARY STEREOCENTERS AT ALPHA(α)-POSITION | NANAYNG TECHNOLOGICAL UNIVERSITY (SG) | 2014-07-17 | — | — | WO | disclosed |
| EP-1656354-A1 | TETRAHYDROQUINAZOLINE DERIVATIVES AS CFR ANTAGONISTS | F.HOFFMANN-LA ROCHE AG (CH) | 2006-05-17 | — | — | EP | disclosed |
| US-20050107373-A1 | E.g., 1-phenyl-8-(2-phenyl-cyclohexyl)-1,3,8-triaza-spiro[4.5]decan-4-one; activation of N-methylaspartic acid receptors via Glycine (Gly t-1) inhibition; psychoses; analgesics; neurodegenerative and psychological disorders; schizophrenia; cognition activators; antidepressants; Alzheimer's disease | F. HOFFMANN-LA ROCHE AG (CH) | 2005-05-19 | — | — | US | disclosed |
| WO-2005040166-A1 | TRIAZA-SPIROPIPERIDINE DERIVATIVES FOR USE AS GLYT-1 INHIBITORS IN THE TREATMENT OF NEUROLOGICAL AND NEUROPSYCHIATRIC DISORDERS | F.HOFFMANN-LA ROCHE AG (CH) | 2005-05-06 | — | — | WO | disclosed |
| WO-2005040166-A1 | TRIAZA-SPIROPIPERIDINE DERIVATIVES FOR USE AS GLYT-1 INHIBITORS IN THE TREATMENT OF NEUROLOGICAL AND NEUROPSYCHIATRIC DISORDERS | F.HOFFMANN-LA ROCHE AG (CH) | 2005-05-06 | — | — | WO | disclosed |
| US-20050038052-A1 | Tetrahydroquinazolines and dihydrocyclopentapyrimidines as CRF antagonists | ROCHE PALO ALTO LLC | 2005-02-17 | — | — | US | disclosed |
| WO-2005014557-A1 | TETRAHYDROQUINAZOLINE DERIVATIVES AS CFR ANTAGONISTS | F.HOFFMANN-LA ROCHE AG (CH) | 2005-02-17 | — | — | WO | disclosed |
| US-4684396-A | Triazole and imidazole compounds useful as plant growth regulators and fungicides | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1987-08-04 | — | — | US | disclosed |
| EP-0153797-A1 | Heterocyclic compounds | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1985-09-04 | — | — | EP | disclosed |
| EP-0073849-A1 | Novel phenyl-1,2,3,4-tetrahydrocarbazoles, their preparation and pharmaceutical compositions containing them | SCHERING CORPORATION (US) | 1983-03-16 | — | — | EP | disclosed |
| US-4292323-A | Phenyl-1,2,3,4-tetrahydrocarbazoles and use thereof | SCHERING CORPORATION (US) | 1981-09-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050107373-A1 | E.g., 1-phenyl-8-(2-phenyl-cyclohexyl)-1,3,8-triaza-spiro[4.5]decan-4-one; activation of N-methylaspartic acid receptors via Glycine (Gly t-1) inhibition; psychoses; analgesics; neurodegenerative and psychological disorders; schizophrenia; cognition activators; antidepressants; Alzheimer's disease | GRIN1, GRIN2A, GRM1 | KDM4E 3291/4885SMN1; SMN2 1887/4885MAPT 136/4885 |
| US-20240254095-A1 | NMDA Receptor Antagonist and Use Thereof | GRIN2B, GRIN1, GRIN3A | KDM4E 2445/4885SMN1; SMN2 1445/4885MAPT 156/4885 |
| US-20050038052-A1 | Tetrahydroquinazolines and dihydrocyclopentapyrimidines as CRF antagonists | CRHR1, AVPR2, CRHR2 | KDM4E 3115/4885SMN1; SMN2 2846/4885MAPT 3071/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.